Results 211 to 220 of about 104,861 (298)

Efficacy and immunogenic effects of Tumor Treating Fields (TTFields) in preclinical models of pancreatic ductal adenocarcinoma, with and without gemcitabine/nab‐paclitaxel

International Journal of Cancer, Volume 158, Issue 12, Page 3091-3100, 15 June 2026.
What's new? Adaptive immune responses are typically limited in pancreatic ductal adenocarcinoma, resulting in minimal efficacy of immune checkpoint inhibitors. Tumor Treating Fields (TTFields) therapy, which uses low‐intensity intermediate‐frequency electric fields to disrupt cancer cell processes, has been approved for certain cancers.
Tal Kan, Tharwat Haj Khalil, Yiftah Barsheshet, Tali Voloshin, Lilach Koren, Bella Koltun, Cfir David, Kerem Wainer‐Katsir, Avital Vorontsova, Boris Brant, Simona Zisman‐Rozen, Hila M. Ene, Roni Frechtel‐Gerzi, Shay Cahal, Anat Klein‐Goldberg, Lena Lifshitz, Efrat Zemer Tov, Mai Shai, Adi Haber, Moshe Giladi, Uri Weinberg, Yoram Palti   +21 more
wiley   +1 more source

Editorial: PARP inhibitors resistance: new insights in ovarian cancer therapy. [PDF]

Front Oncol
Fiste O, Liontos M, Labidi-Galy SI.
europepmc   +1 more source

Pharmacokinetic Drug–Drug Interaction Potential of Oral Anticancer Drugs

Clinical Pharmacology &Therapeutics, Volume 119, Issue 6, Page 1614-1627, June 2026.
Drug–drug interaction (DDI) management is critical for safe and effective use of oral anticancer drugs (OADs). Our study objectives were to (i) compile clinically relevant pharmacokinetic (PK) DDI mechanisms for OADs and (ii) assess the prevalence of PK potential DDIs (PDDIs) in patients with advanced solid cancers.
Fatimah Alhurayri, Islam R. Younis, Shadia I. Jalal, Theodore F. Logan, Rohan Maniar, Steven M. Bray, Sara K. Quinney, Zeruesenay Desta, Todd C. Skaar, James E. Tisdale, Tyler Shugg   +10 more
wiley   +1 more source

PAK1 inhibition synergistically enhances the anti-tumor efficacy of PARP inhibitors in ovarian cancers. [PDF]

Genes Dis
Li C, Li X, Gao M, Deng M, Li YX, Lou Z.
europepmc   +1 more source

Clinical trial of safety and antitumor activity of farletuzumab ecteribulin in patients with platinum‐resistant ovarian cancer: Phase I expansion results

International Journal of Gynecology &Obstetrics, Volume 173, Issue 3, Page 1334-1342, June 2026.
Abstract Objective In the dose‐escalation part of Study 101, which included multiple tumor types, objective responses were observed in 10 of 22 patients across multiple dose levels of farletuzumab ecteribulin (FZEC). We explored the safety/antitumor activity of FZEC in patients with platinum‐resistant ovarian cancer (PROC) from the Study 101 expansion ...
Kan Yonemori, Mayu Yunokawa, Koji Matsumoto, Kazuhiro Takehara, Kosei Hasegawa, Yasuyuki Hirashima, Hidenori Kato, Hiroki Ikezawa, Yohei Otake, Wataru Yusa, Takuma Miura, Shin Nishio   +11 more
wiley   +1 more source

Development of a Synthetic Lethality-Based Combination Therapy Using LIG1 and PARP Inhibitors for Prostate Cancer. [PDF]

Cancer Sci
Tani M, Hatano K, Ishizuya Y, Oka T, Kanaki T, Inoguchi S, Yoshimura A, Horibe Y, Liu Y, Nesrine S, Okuda Y, Yamamoto A, Uemura T, Yamamichi G, Hayashi T, Yamamoto Y, Kato T, Kawashima A, Yamaguchi T, Obika S, Yusa K, Nonomura N, Nimura K.   +22 more
europepmc   +1 more source

RAGE Re‐Expressed at Myofibre Level Drives Muscle Wasting in Cancer Conditions

Journal of Cachexia, Sarcopenia and Muscle, Volume 17, Issue 3, June 2026.
ABSTRACT Background Cancer cachexia (CC) is a highly debilitating syndrome characterized by loss of body and muscle weight affecting most advanced cancer patients. The receptor for advanced glycation end‐products (RAGE) is expressed by several cell types and sustains the inflammatory response in acute and chronic diseases. Total ablation of RAGE (Ager−/
Sara Chiappalupi, Giulia Gentili, Laura Salvadori, Martina Paiella, Marcello Manfredi, Vittoria Federica Borrini, Kaamashri Mangar, Ann Marie Schmidt, Maurizio Muscaritoli, Francesca Riuzzi, Guglielmo Sorci   +10 more
wiley   +1 more source

Exploring the radiochemistry of PARP inhibitors: a new era in therapy and imaging. [PDF]

EJNMMI Radiopharm Chem
Destro G, Rizzo R, Rua C, Azimi RR, Morbelli S.   +4 more
europepmc   +1 more source

Fatty Acid Metabolism in Health and Cancer: From Fundamental Mechanisms to Therapeutic Application

MedComm, Volume 7, Issue 6, June 2026.
The modulation of the TME by fatty acid metabolism primarily occurs through four key pathways: inflammation regulation, signal transduction, translation to TME, and oxidative stress. ABSTRACT Fatty acid metabolism (FAM) plays a vital role in maintaining health by supporting energy production, cellular structure, and signaling processes.
Na Hang, Runkang Zhao, Fan Zhang, Dandan Guo, Qing Li, Zhijun Shen, Ruiqing Gao, Chenyu Gao, Zhao Xie, Sentao Fu, Peng Luo, Bufu Tang, Ling Wang   +12 more
wiley   +1 more source